Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion type Assertion NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_head.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion description "[Furthermore, Gal-9 expression could significantly stratify the patients in early (grades I?+?II) tumor, node, and metastasis (TNM) stage (OS: P?=?0.005; RFS: P?=?0.041) and low (grades 1?+?2) Fuhrman grade (OS: P?=?0.004; RFS: P?=?0.006).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_provenance.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion evidence source_evidence_literature NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_provenance.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion SIO_000772 25716202 NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_provenance.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion wasDerivedFrom befree-2016 NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_provenance.
- NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_assertion wasGeneratedBy ECO_0000203 NP1266321.RAcE71zdFbG-MYhkqPbqf07jljh71Va_0u-YDw0du0kDc130_provenance.